Application of Half-life Extended Drug in Neurodegenerative Diseases

For Research Use Only. Not for Clinical Use.

After years of development, considerable evidence has accumulated on various half-life extended services. Creative Biolabs is fully equipped to provide quality services according to customer project needs.

Factors of neurodegenerative disease. Fig.1 Factors of neurodegenerative disease. (Sheikh, 2013)

Introduction of Neurodegenerative Diseases

Neurodegeneration refers to slow and progressive dysfunction of neurons and axons in the nervous system, and it is the typical characteristic of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, neurotropic viral infections, and multiple sclerosis. Neurodegenerative diseases affect people all over the world. The reasons for neurodegeneration are considered multifactorial, which mainly include genetic, environmental, and endogenous factors. For example, several neurodegenerative diseases, such as Alzheimer's, Parkinson's are the consequence of misfolding of proteins. Furthermore, mitochondrial dysfunction, oxidative stress, and environmental factors also have an important impact on the occurrence of neurodegenerative diseases.

Therapies for Neurodegenerative Diseases

In recent years, there has been an increased interest in the treatment of neurodegenerative disorders. Therapies such as stem cell therapy, nanotechnology, gene transfer therapy, and medicinal-chemistry-based treatment have caused a lot of attention. In addition, antisense oligonucleotides are emerging as a promising therapeutic platform for the treatment of neurodegenerative diseases.

Application of Half-life Extended Drug in Neurodegenerative Diseases

  • GLP-1
    Analogues of the incretins glucagon-like peptide 1 (GLP-1) have been developed to treat several diseases. Experiments showed that GLP-1 analogues Val(8)GLP-1 and liraglutide are related to neurodegenerative diseases. Two GLP1 analogues, exendin-4, and liraglutide have been used for other diseases, these drugs showed potential as treatments for neurodegenerative diseases. One great disadvantage of GLP-1 is the short half-life. To extend the half-life of GLP-1, modifications to the peptide have been made. The peptide modifications involve the addition of fatty acids to the GLP-1 molecule which strengthens the combination with blood proteins and thereby protects it from being degraded.
  • Complement activation
    Complement activation contributes to the pathology of a variety of degenerative diseases. Therefore, the soluble recombinant forms of the naturally occurring membrane complement regulatory proteins (CRP) have been exploited. To design better therapeutics based on CRP, soluble CRP with Fc domains was invented. Some research results indicate that compared with soluble DAF, the new combination had a much longer half-life.
  • 4-AP
    4-aminopyridine (4-AP) was often used in the treatment of neurological diseases. Early clinical applications of 4-AP were usually used in powder form. The immediate release formulation is characterized by a short half-life. Recently, a prolonged release matrix tablet form of 4-AP has been developed and is proven to have a longer half-life.

Based on extensive knowledge and rich experience, we are confident in offering half-life extended services for neurodegenerative diseases. Please contact us for detailed information.


  1. Sheikh, S.; et al. Neurodegenerative diseases: multifactorial conformational diseases and their therapeutic interventions. Journal of neurodegenerative diseases. 2013.
Online Inquiry

Please submit a detailed description of your project. Our industry-leading scientists will review the information provided as soon as possible. You can also send emails directly to for inquiries.

For Research Use Only. Not for Clinical Use.